论文部分内容阅读
目的:通过临床试验对比,探讨参一胶囊联合FuP化疗方案对胃癌疗效的促进作用.方法选取我院2010年1月~2012年3月间确诊并收治的胃癌患者100例,随机分为对照组和实验组.对照组使用化疗配合安慰剂治疗,实验组,使用参一胶囊替换安慰剂治疗.观察两组患者的疗效,不良反应等情况,并作统计学分析.结果实验组总有效率和生活质量评分方面优于对照组,且差异具有统计学意义(P<0.05).实验组白细胞计数、血红蛋白、血小板减少情况明显低于对照组,差异具有统计学意义,其他不良反应指标无统计学差异.结论在化疗过程联合使用参一胶囊治疗胃癌,可明显提高疗效,有助于延长患者的生存期,值得临床推广. “,”Objective To compare the clinical trials to explore the promotion of the role of SHENYIJIAONANG combined FuP a chemotherapy treatment for stomach cancer effect.Methods Gastric cancer patients in our hospital in January 2010 between March 2012 diagnosed and treated 100 cases,randomly divided into control and experimental groups.The control group using chemotherapy with placebo.Experimental group, replacing placebo. the use of SHENYIJIAONANG..Therapeutic effects were observed, and adverse reactions, etc., and for statistical analysis. Results The experimental group, the total efifciency and quality of life scores better than the control group,And the difference was statistically signiifcant (P〈0.05).The experimental group leukocyte count, hemoglobin, thrombocytopenia cases significantly lower than the control group, the difference was statistically significant, other indicators of adverse reactions was no signiifcant difference.Conclusion In the course of chemotherapy combined use of SHENYIJIAONANG treatment of gastric cancer, can signiifcantly improve the therapeutic effect, helps to prolong survival of patients, worthy of promotion.